DIRS.INFO The most relevant business & tech news

☆ You can now get Ozempic at Costco — but don't expect big savings
▼ + stars: | 2024-04-03 | by ( Alex Bitter | ) www.businessinsider.com time to read: +3 min

Costco is now selling the weight loss drug Ozempic through a partnership with health startup Sesame. Still, that doesn't cover the cost of the GLP-1 drug, which has gained popularity but can be costly. Now, you can get a prescription for the weight loss drug Ozempic through the retailer, too. For $179, members can get a prescription for the GLP-1 weight loss drug plus a meeting with a doctor or specialist. Ozempic, Wegovy, and other GLP-1 drugs have gained popularity among people trying to lose weight over the last few years.

Persons: —, Michael DiLorenzo, DiLorenzo, Sesame, weren't, Michael Botta Organizations: Costco, Service, CNN, Business, Sesame, Novo Nordisk Locations: Denmark

☆ Costco begins offering Ozempic prescriptions to some members
▼ + stars: | 2024-04-02 | by ( Nicole Goodkind | ) edition.cnn.com time to read: +2 min

The warehouse retailer is now offering its US members access to prescriptions for GLP-1 weight loss drugs through its low-cost health care partner Sesame. Costco first partnered with Sesame, a direct-to-consumer health care marketplace that connects medical providers nationwide with consumers, last fall when it began offering its members online health checkups for as low as $29. “The number one search term of Costco members seeking primary care on Sesame was around weight loss,” Goldhill said in an interview with USA Today. JPMorgan researchers estimate that 30 million people may be taking GLP-1 drugs by 2030, or around 9% of the US population. It also made a $100 million-plus deal to buy Sequence, a telehealth business that can offer virtual prescriptions, where appropriate, to patients for these weight loss drugs.

Persons: Sesame, David Goldhill, ” Goldhill, WeightWatchers Organizations: New, New York CNN, Costco, USA, CNN, JPMorgan Locations: New York

☆ A new Ozempic rival helps patients lose fat, but keep their muscle — the holy grail for a weight-loss drug
▼ + stars: | 2024-03-29 | by ( Hilary Brueck | ) www.businessinsider.com time to read: +3 min

A new GLP-1 drug, pemvidutide, helped patients lose fat while guarding muscle, like exercise does. That's impressive when you compare it to existing GLP-1 drugs like Ozempic and Wegovy (semaglutide), or Mounjaro and Zepbound (tirzepatide). This is why doctors recommend patients on weight loss drugs do some strength training in tandem with their medication. Pemvidutide, like tirzepatide is a two-part drug that combines a GLP-1 drug with another drug in a single shot. "There is a growing appreciation that the quality of weight loss is as important as the quantity of weight loss," Scott Harris, Altimmune's chief medical officer, said in a release.

Persons: Drugmakers Eli Lilly, —, Drugmaker Altimmune, Altimmune, Scott Harris, Eli Lilly, FierceBiotech, Versanis Organizations: Novo Nordisk, Service Locations: Altimmune, GLP

☆ Altimmune says weight loss drug minimized muscle loss in trial results, which may set it apart
▼ + stars: | 2024-03-27 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Some health experts have said that obesity drugs could shrink critical muscle mass, which could raise the risk of injuries and decrease strength. Those results are similar to those often seen with diet and exercise programs for weight loss. "There is a growing appreciation that the quality of weight loss is as important as the quantity of weight loss." For example, Eli Lilly is testing whether combining its weight loss drug with a monoclonal antibody from Versanis Bio might help patients lose weight while preserving muscle mass. The pharmaceutical giant recently acquired Versanis, which is part of a slate of companies targeting the muscle-loss aspect of weight loss.

Persons: Altimmune, Eli Lilly, Scott Harris Organizations: Novo Nordisk, Novo Nordisk's Ozempic Locations: Altimmune's, Novo

☆ Weight-loss drug Wegovy can be marketed for heart benefits after FDA label update
▼ + stars: | 2024-03-08 | by ( Meg Tirrell | ) edition.cnn.com time to read: +4 min

The label expansion may improve insurance coverage for Wegovy, which costs more than $1,300 per month out of pocket before any discounts. Many insurers, including Medicare, don’t cover drugs for weight loss, leaving patients scrambling to afford them. “This patient population has a higher risk of cardiovascular death, heart attack and stroke,” he added. More studies need to be done to show whether there are heart benefits for people who haven’t had a cardiac event. Wegovy continues to be in shortage, along with other GLP-1 medicines, as drugmakers struggle to keep up with demand.

Persons: CNN — Wegovy’s, –, Dr, Harlan Krumholz, hasn’t, Eli Lilly, Wegovy, John Sharretts, haven’t, it’s, Sanjay Gupta, Jody Dushay, Beth, Dushay, Novo, Doug Langa, ” Organizations: CNN, US Food and Drug Administration, Yale University, Yale New Haven Hospital, Novo Nordisk, Diabetes, ”, CNN Health, Beth Israel Deaconess Medical Center, Harvard Medical School, Novo Nordisk’s, North America Operations

☆ Oprah has left WeightWatchers, sending stocks spiraling and spelling doom for the diet of our foremothers
▼ + stars: | 2024-02-29 | by ( Mia De Graaf | Rachel Hosie | ) www.businessinsider.com time to read: +7 min

Oprah Winfrey will not seek reelection to the board of WW International, known as WeightWatchers. It was a surprising time to jump on board — WeightWatchers had been shedding users, and its stock price was dwindling. AdvertisementDespite not naming the brand, there was an immediate spike in demand for GLP-1 medications — the popular new class of weight-loss drugs. That same day, WW added a weight-loss drug arm to its business, acquiring Sequence, a service that provides weight-loss drugs. AdvertisementLong-term, WW needs to find a new identityOver time, WW will benefit from being a purveyor of hard-to-access weight-loss drugs.

Persons: Oprah Winfrey, —, Oprah giveth, Oprah taketh, maven, Winfrey, — WeightWatchers, Axios, Oprah, Forbes, Craig, Alex Fuhrman, Winfrey's, We're, Atkins Organizations: WW International, Service, SEC, Guardian, People Magazine, MarketWatch, Mayo Clinic, Business, Smithsonian's National Museum of, CNBC, Slate Locations: GLP, WeightWatchers

☆ Viking Therapeutics' weight loss drug showed faster results in clinical trials than Ozempic or Wegovy. Here's how it works.
▼ + stars: | 2024-02-28 | by ( ) www.businessinsider.com time to read: +3 min

Biotech company Viking Therapeutics saw stock prices double after a report on weight loss drug VK2735. The new drug could lead to even more weight loss at a faster pace than Ozempic or Mounjaro. Viking Therapeutics, a small California-based biotech company, shared the topline results from a mid-stage trial of its drug VK2735 on February 27. AdvertisementHowever, the early results of clinical trials suggest it could be on par to offer even more weight loss in less time than its competitors. How Viking Therapeutics' weight-loss drug worksVK2735 mimics two hormones that affect weight control.

Persons: —, Eli Lilly, GIP, VK2735 Organizations: Biotech, Viking Therapeutics, Service, Novo Nordisk, Washington Post, Therapeutics, Viking Locations: California

☆ Wall Street thinks this revolutionary gut health stock can triple in value
▼ + stars: | 2024-02-27 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +4 min

Just weeks after its initial public offering, Fractyl Health is catching Wall Street's attention as the next potential biopharmaceutical darling. Analysts are highlighting the company's groundbreaking therapies that directly target the gut and pancreas to ultimately induce Type 2 diabetes maintenance and weight loss. "Growing evidence indicates the gut is a core regulator of metabolism, placing gut dysfunction as a root cause of metabolic disease. Indeed, emerging consensus links modern diets to changes in the gut and pancreas that in turn increase an individual's risk of developing Type 2 Diabetes and obesity," Ulz wrote. gut) root cause of disease, could result in a more durable, disease-modifying treatment, differentiated from current, more burdensome (i.e.

Persons: Morgan Stanley, Jason Gerberry, Michael Ulz's, Ulz, Gerberry, Rejuva, America's Gerberry Organizations: Bank of America, Evercore ISI, Fractyl's, Bank, America's Locations: Fractyl

☆ The questions eating disorder experts have about weight loss medications
▼ + stars: | 2024-02-26 | by ( Madeline Holcombe | ) edition.cnn.com time to read: +8 min

CNN —There is still much researchers don’t know about popular weight loss medications — and those lack of studies could have consequences for eating disorders, according to experts. As the medication become more available, experts said they worry about the impact of these weight loss products on eating disorders. “The eating disorder field is hard because we’re just ignored.”Can these drugs treat binge eating disorder? Binge eating disorder is the most common eating disorder. “A lot of eating disorders do begin with restricted food intake and weight loss,” she said.

Persons: ”, Aaron Keshen, Jennifer Gaudiani, Susan McElroy, Linda, Harry Fath, McElroy, “, ” McElroy, ” Keshen, it’s, Keshen, Gaudiani, ” Gaudiani, “ it’s, ‘, haven’t Organizations: CNN, Nova, Disorder, National Association, Disorders, Gaudiani Clinic, Lindner, of HOPE, University of Cincinnati College of Medicine, International Locations: Nova Scotia, Dalhousie University’s, Halifax , Nova Scotia, United States, Denver, Minnesota

☆ Kelly Osbourne defends using Ozempic for weight loss: 'I think it's amazing'
▼ + stars: | 2024-02-16 | by ( Olivia Singh | ) www.businessinsider.com time to read: +2 min

Read previewKelly Osbourne shared in a recently published interview that she's fully in support of using Ozempic, days after her mother, Sharon Osbourne, made headlines criticizing the drug for its effects. "I think it's amazing," Osbourne told E! Stars like Amy Schumer and Chelsea Handler have been outspoken about their negative experiences using Ozempic. Sharon previously cautioned against using Ozempic and said losing weight can become addicting. News, Kelly explained why she thinks the weight-loss drug is spoken about in a negative light.

Persons: —, Kelly Osbourne, she's, Sharon Osbourne, Osbourne, who's, Jae C, Amy Schumer, Chelsea Handler, Sharon, Kelly Organizations: Service, CBS, Business, Guardian, BI

☆ How to access the new weight loss drugs
▼ + stars: | 2024-02-15 | by ( Andrea Kane | ) edition.cnn.com time to read: +7 min

(CNN) — By now, it is pretty clear that the new weight loss and diabetes medications have achieved blockbuster status. Unlike previous weight loss medications, they are pretty effective at helping people lose weight and keep it off — between around 15% to 20% of body weight — with relatively few side effects (although some people can’t tolerate them, and a fraction of patients experience more severe side effects). Zepbound, the newly approved weight loss drug from Eli Lilly, may be easier to find. “Otherwise, some physicians are prescribing older, generic weight loss medications that can be helpful for some patients.”These drugs are not right for everyoneFor many people, the cultural pressure to look a certain way is high. And join us next week on the Chasing Life podcast when we talk to WeightWatchers CEO Sima Sistani about whether these new weight loss drugs really signal the end of diet culture.

Persons: Sanjay Gupta ”, Eli Lilly, Goldman Sachs, Meg Tirrell John Nowak “, Meg Tirrell, Sanjay Gupta, ” Tirrell, “, ” Eli Lilly, Tirrell, ”, Sima Sistani Organizations: CNN, —, Trilliant Health, Novo Nordisk, US Food and Drug Administration, “, Nordisk, ”

☆ Sharon Osbourne swears off weight loss and cosmetic treatments after experiencing the downsides of Ozempic
▼ + stars: | 2024-02-11 | by ( Eve Crosbie | ) www.businessinsider.com time to read: +3 min

Read previewSharon Osbourne has expressed regret over taking the buzzy weight-loss drug Ozempic, stating that she now weighs less than 100 pounds and "can't put on weight." In an interview with The Guardian, Osbourne, 71, highlighted the downsides of Ozempic, a diabetes drug that also causes weight loss. She said that after dropping 42 pounds in four months, she's now "through with the weight loss and all that cosmetic stuff." Osbourne has previously talked about her experience taking the weight loss drug. Sharon Osbourne said her husband Ozzy Osbourne claims she looks like Nancy Reagan following her weight loss.

Persons: —, Sharon Osbourne, Osbourne, she's, Ozzy Osbourne, Nancy Reagan, Gregg DeGuire, I've, it's, Ozempic, Elon Musk, Charles Barkley, Amy Schumer Organizations: Service, Guardian, Business, Daily Mail, The Recording, Ozempic, FDA, The Times

☆ Ro, the $7 billion healthcare startup, has a high-stakes strategy to take off-brand Ozempic mainstream
▼ + stars: | 2024-02-07 | by ( ) www.businessinsider.com time to read: +11 min

The $7 billion healthcare startup Ro, which has been prescribing brand-name weight-loss shots since January 2023, now offers compounded semaglutide to patients enrolled in its weight-management program. Nonetheless, Ro is the first prominent healthcare company to effectively endorse compounded semaglutide by prescribing it. A poor-quality compounded drug might simply be a dud and a waste of money. But while compounding pharmacies are subject to FDA and state regulations, states are the main regulators, and their oversight is patchy. Michael Siluk/UCG/Universal Images Group via Getty ImagesIt's hard to know if any given vial of compounded semaglutide is safe.

Persons: Wegovy's, Ro, drugmakers, Eli Lilly's, Eli Lilly's Mounjaro, Scott Gottlieb, Michael Siluk, That's, they've, Ozempic, Eli Lilly, Eric Kastango, they're, Kastango, aren't, Al Carter, Sarah Jones Simmer, Spencer Nadolsky, WeightWatchers, Tim Church, Wondr, it's, hasn't Organizations: Business, Novo Nordisk's Wegovy, US Food and Drug Administration, FDA, Novo Nordisk's Ozempic, Getty, Novo Nordisk, USP, National Association of, Pharmacy, Health Locations: Novo, Massachusetts, Austria, New York City

☆ Eli Lilly says weight loss drug shows promise as treatment for fatty liver disease
▼ + stars: | 2024-02-06 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Eli Lilly on Tuesday said its highly popular drug used for weight loss and diabetes showed promise as a treatment for fatty liver disease in a mid-stage trial. The condition is characterized by excess fat build-up and inflammation in the liver and can lead to liver scarring, also known as fibrosis. The trial followed around 190 adults with MASH with severe stages of liver scarring, Eli Lilly executives said on an earnings call Tuesday. It was less clear how much the drug reduced liver scarring, which was the second aim of the trial. Eli Lilly is "equally encouraged" by tirzepatide's results in reducing liver scarring, the company's chief scientific officer Dan Skovronsky said on the call.

Persons: Eli Lilly’s, Eli Lilly, tirzepatide, Dan Skovronsky, David Risinger, Eli Lilly's Organizations: Leerink, Novo Nordisk Locations: New York City, U.S

☆ Tirzepatide: Weight loss drug helps significantly lower blood pressure in adults who are overweight or obese, study finds
▼ + stars: | 2024-02-05 | by ( Mira Cheng | ) edition.cnn.com time to read: +6 min

The participants had their blood pressure monitored for a day before beginning treatment and again after nine months of weekly tirzepatide injections. The results showed a significant decrease in the participants’ systolic blood pressure, the top number in blood pressure readings, which is a strong predictor of heart disease. It works similarly to semaglutide, the active compound in the weight loss drug Wegovy and its sister diabetes drug, Ozempic. Although there are effective blood pressure medications available, only about a quarter of people with hypertension have adequately controlled blood pressure, Hall said. He views the weight loss effect of the drug as a pleasant side effect that will make people more likely to take their medication.

Persons: —, Eli Lilly, ”, Harlan Krumholz, Michael E, Wegovy, it’s, Ania Jastreboff, Hall, Krumholz, tirzepatide, Dr, Sanjay Gupta, CNN’s Meg Tirrell Organizations: CNN, American Heart Association, Food and Drug Administration, Yale University, Department of Medicine, University of Mississippi Medical Center, Yale Obesity Research Center, CNN Health Locations: United States

☆ What to know about medications like Ozempic, Wegovy, Mounjaro and Zepbound for weight loss
▼ + stars: | 2024-02-03 | by ( Andrea Kane | ) edition.cnn.com time to read: +8 min

Editor’s note: Season 9 of the podcast Chasing Life With Dr. Sanjay Gupta explores the intersection between body weight and health. But anyone who has ever dieted can tell you that losing weight is hard and that long-term weight loss requires sustained effort, which can sometimes feel Herculean, even impossible. If you are considering starting one of these medications, Moreno recommends keeping these five facts in mind. “On average, with semaglutide, the weight loss average can be close to 15%. This is the time to start changing some eating patterns that will be beneficial for weight loss.

Persons: Sanjay Gupta, Ozempic, It’s, Jorge Moreno, Moreno, ‘ You’ve, ”, ” Moreno, “, Tirzepatide, Food and Drug Administration — “, They’re, ” They’re, —, “ It’s, GERD, ” It’s, ’ ” Moreno Organizations: CNN, Yale School of Medicine, LinkedIn, Food and Drug Administration

☆ Norway's giant wealth fund touts possibility of Novo Nordisk, Eli Lilly joining the trillion-dollar club
▼ + stars: | 2024-01-31 | by ( Sam Meredith | ) www.cnbc.com time to read: +1 min

A pharmacist displays boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, at Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. Norway's giant wealth fund, the world's largest, touted the possibility that Danish drugmaker Novo Nordisk and U.S. rival Eli Lilly could be on course to become the first healthcare members of the trillion-dollar club. Novo Nordisk, Europe's largest firm by market capitalization, on Wednesday reported stronger-than-anticipated 2023 earnings, as sales of its hugely popular drug Wegovy continued to soar. The largest pharmaceutical company in the world by market value, Eli Lilly currently stands at roughly $612 billion. NBIM, the world's biggest single stock market investor, holds a 2.5% stake in Novo Nordisk and a 0.98% stake in Eli Lilly, according to LSEG data.

Persons: Eli Lilly, Wegovy, Gemma Game, Eli Lilly's Zepbound Organizations: Novo Nordisk, Pharmacy, Norges Bank Investment Management, Nordisk's Ozempic Locations: Provo , Utah, U.S, Danish, Europe's

☆ 'Botched' star Terry Dubrow calls Ozempic 'a miracle' but admits it takes 'all the joy of eating away'
▼ + stars: | 2024-01-22 | by ( Amanda Goh | ) www.businessinsider.com time to read: +2 min

"Botched" star and plastic surgeon Terry Dubrow told Page Six that he tried Ozempic. Dubrow called the weight-loss drug "a miracle" but admitted it took "all the joy of eating away." He said he wanted to see what it's like if you're not diabetic and "only have 10-15 pounds to lose." Advertisement"Botched" star Terry Dubrow says he tried Ozempic but gave it up because it took "all the joy of eating away." In a Page Six interview alongside costar Paul Nassif, the plastic surgeon admitted to giving the weight-loss drug a go because he was curious about its effects.

Persons: Terry Dubrow, Dubrow, —, Paul Nassif, Evan Real, Heather Dubrow — Organizations: Service, Page, Housewives, FDA Locations: Orange

☆ A doctor lost 50 pounds and has kept it off for years after ditching fad diets. She eats high-protein food and does intermittent fasting.
▼ + stars: | 2024-01-18 | by ( Rachel Hosie | ) www.businessinsider.com time to read: +7 min

Research shows that there is nothing special about intermittent fasting for weight loss, and it doesn't work for everyone because it can be challenging to maintain. But it helps some people stick to a calorie deficit, which is required for weight loss. Protein is helpful for weight loss because it keeps you feeling full and helps the body maintain muscle during a calorie deficit. AdvertisementAfter a few months, her new lifestyle felt normal and she continued intermittent fasting after finishing her weight loss phase. Grunch believes weight loss is about mindsetGrunch is now aiming to maintain her weight and will see how that goes without medication.

Persons: Betsy Grunch, Grunch, —, Carbs, I've Organizations: Service, aha, Research Locations: Atlanta , Georgia

☆ Questions and answers for weight loss medications semaglutide and tirzepatide
▼ + stars: | 2024-01-17 | by ( Katia Hetter | ) edition.cnn.com time to read: +10 min

CNN —As prescriptions for popular weight loss drugs have soared, the class of medications known as GLP-1 agonists is changing the way people think about how to lose weight. Initially developed to treat type 2 diabetes, medications like semaglutide and tirzepatide have also been shown to be effective in promoting weight loss. Also, some people would do well without medications and could have sufficient weight loss with changes in diet and exercise. Wen: The FDA-approved versions of semaglutide and tirzepatide for weight loss are called Wegovy and Zepbound. CNN: Are there certain medications that preclude you from taking the weight loss drugs at the same time?

Persons: Leana Wen, Wen, Michael Siluk, tirzepatide, It’s, Eli Lilly Organizations: CNN, US Food and Drug Administration, George Washington University, FDA, BMI, Getty Images CNN, The New England, of Medicine, Novo Nordisk, semaglutide Locations: The

☆ What weight tells us about our health
▼ + stars: | 2024-01-17 | by ( Dr. Sanjay Gupta | ) edition.cnn.com time to read: +12 min

(CNN) — If you’ve been paying attention to health news recently, you may have noticed a subtle but real shift in the way society discusses body weight. Beyond health care dollarsDespite changing attitudes about larger bodies, excess weight does carry a price. From a health care standpoint, it costs the country a lot of money. According to a study published in the journal The Lancet in 2020, 27% of total health care expenditures in 2016 — about $730.4 billion — could be attributed to “modifiable risk factors” for preventable health conditions like cardiovascular disease. That was eight years ago, when our total health care expenditure was $2.7 trillion, according to the study.

Persons: you’ve, We’re, Dr, Fatima Cody Stanford, “, They’re, Adolphe Quetelet, Ancel Keys, ”, ” Stanford, Morgan, That’s, we’ll, Daniel Lieberman, who’ll, Oprah Organizations: CNN, American Medical Association, Massachusetts General Hospital, Harvard Medical School, National, bloodwork, Harvard Locations: Belgian

☆ Opinion: What Oprah gets right about diet culture
▼ + stars: | 2024-01-11 | by ( Opinion Adrienne Bitar | ) edition.cnn.com time to read: +6 min

How could she, the queen of WeightWatchers and doyenne of dieting, be abandoning the equation of diet + exercise = slim? Taking weight-loss drugs, rejecting diet culture or choosing to diet are all valid health decisions. Just look at the tragic history of diet drugs. When considered in this context, semaglutide isn’t the weight loss panacea it may appear to be. Oprah and the millions of other Americans on prescription semaglutide and similar medications should be respected — or at least not ridiculed — for ignoring the insults and choosing what’s right for them, drug or no drug, diet or no diet.

Persons: Adrienne Bitar, ”, Oprah Winfrey, WeightWatchers, Oprah, couldn’t, Cancer, dieters, “, gaunt, Jimmy Kimmel, Atkins “, John Harvey Kellogg, Kellogg, dieter, — Organizations: “, Studies, Cornell University, CNN, ”, Federal Food

☆ Oprah's flip on weight loss drugs is a sign of what's to come for the 'Ozempic trade' in 2024
▼ + stars: | 2023-12-25 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +10 min

Lilly's Zepbound recently entered the weight loss market, and is off to a strong start. But what's ahead for the weight loss trade in 2024? Beyond weight loss One of 2023's most pivotal events in the space was Novo Nordisk's release of top line results from its Select trial in August . In 2023, the exuberance around weight loss drugs roiled markets in many unexpected ways. The affected companies have also been very vocal in addressing how they plan to coexist with these weight loss products.

Persons: Oprah Winfrey, Eli Lilly, they've, Lilly's, Lilly's Zepbound, Andy Acker, Janus Henderson's, Lilly, Novo, FactSet, Acker, Janus, Buzz, Gregory Renza, Renza, Goldman Sachs, Chris Shibutani, Mike Kratky, Kratky, Dexcom, Leerink, Winfrey, I've, Winfrey's, Michael Bloom Organizations: Novo Nordisk, Wall Street, Wall, RBC Capital, Pfizer, Structure Therapeutics, AstraZeneca, Leerink, Nestle, Oprah Daily, Winfrey, International Locations: Friday's, Eccogene, MedTech, 3Q23

☆ Healthcare companies are promising to help patients quit Wegovy. There's just one problem with that.
▼ + stars: | 2023-12-19 | by ( ) www.businessinsider.com time to read: +11 min

Inkinen said Virta can help patients quit GLP-1 drugs and keep weight off by adjusting the foods they eat to help them feel full, similar to how the drugs reduce feelings of hunger. About 82% of patients taking Wegovy experience gastrointestinal issues like nausea and diarrhea. WeightWatchers didn't provide Business Insider with published data to support its claims that it can help people keep weight off after quitting weight-loss drugs. AdvertisementHe also advises the weight-loss startup Calibrate, which tapers some patients off GLP-1 drugs after they reach a certain body-mass index. GLP-1 drugs also slash the risk of heart attacks, strokes, and cardiac-related death.

Persons: —, Michael Albert, aren't, Sami Inkinen, Inkinen, Virta, Michael Siluk, Noom's, Linda Anegawa, Carolina Rudah, tirzepatide, Mounjaro, Zepbound —, Eli Lilly, Ozempic, Wegovy, Randy Seeley, Seeley, Robyn Phelps, it's, Robert Kushner, Kushner, Florian Gaertner, It's, Albert, Lisa, she's, I'm Organizations: Service, Business, FDA, Virta, Getty, Nordisk, Michigan Nutrition Obesity Research, University of Michigan, Novo Nordisk, Northwestern University Locations: Denver, Michigan

☆ US obesity docs expect Lilly weight-loss drug to show similar heart benefit as Wegovy
▼ + stars: | 2023-12-01 | by ( Patrick Wingrove | ) www.reuters.com time to read: +5 min

REUTERS/Mike Segar Acquire Licensing RightsDec 1 (Reuters) - Some leading U.S. obesity specialists say they expect Eli Lilly’s (LLY.N) powerful weight-loss drug Zepbound will produce the same or similar heart benefits as Novo Nordisk’s (NOVOb.CO) popular Wegovy as they belong to the same class of medicines. In Novo's pivotal Wegovy trial involving 17,604 overweight and obese people without diabetes, the drug reduced incidence of heart attack, stroke or heart-related death by an impressive 20%. The product, which has the same active ingredient - tirzepatide - as its previously approved diabetes drug Mounjaro, is expected to start shipping it before the end of the year. They said they would readily prescribe Wegovy (semaglutide) if their patients' insurance did not cover Lilly’s drug, or if future trial results do not produce similar heart benefits. Lilly declined to comment on doctors' views that Zepbound might have the same or similar cardiovascular benefits as Wegovy.

Persons: Eli Lilly, Mike Segar, Eli Lilly’s, Lilly, Danish drugmaker, Edmond Wickham, Emily, Zepbound, Tirzepatide, ”, Rohit Kedia, Novo, Chad Weldy, semaglutide, tirzepatide, Farxiga, Boehringer Ingelheim, Lilly’s Jardiance, Patrick Wingrove, Caroline Humer, Bill Berkrot Organizations: Company, REUTERS, Novo, Wegovy, Virginia Commonwealth University . The, Virginia Commonwealth University . The U.S . Food, Drug Administration, Wall Street, Barclays, Providence, Stanford University, Thomson Locations: Branchburg , New Jersey, Danish, Virginia Commonwealth University . The U.S, Zepbound, U.S

Search resuls for: "semaglutide"

25 mentions found